Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®
Tuesday, September 2, 2025
Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities
WASHINGTON, Aug. 25, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it has entered into a global software licensing and collaboration agreement with Zhejiang Orient Gene Biotech Co., Ltd. ("Orient Gene") to integrate Neopharma's NEOVAULT® software across Orient Gene's range of Drugs of Abuse (DOA) rapid tests under the Healgen® brand.
Why This Matters
The partnership combines proven rapid drug testing hardware with NEOVAULT®'s digital intelligence, delivering:
-- Tamper-evident capture of results at the point of testing, with
automated audit trails for safety-critical environments.
-- Instant, de-identified analytics to reveal trends by site, shift, and
risk factor--enabling earlier, targeted interventions.
-- Built-in interoperability so results flow securely into HR and clinical
systems for prevention, compliance, and reporting.
Alignment with U.S. Drug Policy Priorities
This collaboration aligns with priorities highlighted by the White House Office of National Drug Control Policy's April 1, 2025 statement:
-- Priority 1 -- Reduce Overdose Fatalities (fentanyl focus): NEOVAULT®
digitizes screening results and can flag fentanyl rapid test results in
real time, producing live 'heat maps' for U.S. authorities.
-- Priority 6 -- Innovate in Research and Data: NEOVAULT® generates
accurate, shareable, and timely data for rigorous analytics and secure
information exchange. This supports modernization of the DOA testing
industry--digitizing workflows and harnessing AI/ML alongside
public-private partnerships to address emerging threats.
Security & Compliance
NEOVAULT® is designed to meet the highest security and privacy standards, including:
-- ISO 27001 international certification for information security
management
-- SOC 2 Type II attestation across all Trust Services Criteria
-- HIPAA U.S. certification for handling, storing, and transmitting
protected health information
-- GDPR-aligned controls supporting covered entities, business associates,
and EU/UK data processors
Executive Commentary
Marcus L'Estrange, Executive Chairman, Neopharma Technologies:
"We are raising the global standard for digital drug testing. By enabling Healgen®'s extensive DOA portfolio with NEOVAULT®, we transform paper-based results into structured intelligence--helping employers act faster and giving policymakers real-time insights."
Byran Fang, President, Orient Gene:
"As a global leader in the field of In-Vitro Diagnostics, Orient Gene is committed to advancing both the accuracy and accessibility of rapid testing. This partnership ensures our customers benefit from the trusted performance of Healgen® devices and the added value of secure, real-time digital reporting."
What Customers Will Get
-- NEOVAULT®-enabled Healgen® test devices: Same simple workflow, now
with guided capture, scannable kit IDs, and real-time reporting of
results.
-- NEOVAULT® ERM platform: A highly secure system for Third Party
Administrators and Drug Testing businesses to create digital reports in
the field with ease. It also provides HR teams with real-time data to
support hiring decisions in minutes, compared to the typical 4-7 day
timeframe.
-- Enterprise connectors: API integrations with common HRIS platforms and
role-based access controls.
About Orient Gene / Healgen®
Orient Gene's Healgen® brand delivers widely used rapid in-vitro diagnostic devices, including multi-panel cups, cassettes, and strips for DOA screening.
About Neopharma Technologies Limited
Neopharma Technologies is an Australian health-technology company focused on digital drug and impairment testing to create safer workplaces globally. Its mission is for NEOVAULT® to become the world's default digital testing platform for point-of-care.
Trademarks: NEOVAULT® is a registered trademark of Neopharma Technologies Limited. Healgen® is a registered brand of Orient Gene.
Policy reference: White House, Office of National Drug Control Policy, Statement of Drug Policy Priorities (April 1, 2025).
View original content to download multimedia:https://www.prnewswire.com/news-releases/neopharma-technologies-and-orient-gene-partner-to-digitize-healgen-drug-test-portfolio-globally-with-neovault-302537917.html
SOURCE Neopharma Technologies Ltd
|
|
|
|
|
 |
Energy Toolbase Launches Energy Storage Partnership with Sungrow to Support PowerStack 255CS and PowerTitan 2.0 | Jan 22, 2026
|
|
RS now offers Phoenix Contact's pioneering new NearFi technology | Jan 22, 2026
|
|
MetaOptics to Showcase Five Breakthrough Metalens-Powered Products at CES 2026 | Jan 22, 2026
|
|
Fresco Raises EUR15m Series C to Power the Future of AI-Driven Cooking and the Connected Kitchen Ecosystem | Jan 22, 2026
|
|
No Assembly Required: Barrett Distribution Centers Powers Maxwood Furniture's West Coast DTC Expansion | Jan 22, 2026
|
|
SCAILIUM Debuts "AI Production Layer" to Overcome GPU Starvation and Slash AI Energy Waste | Jan 22, 2026
|
|
Hesai Recognized as the Only Lidar Company on Morgan Stanley's "Humanoid Tech 25" of Global Robotics Leaders | Jan 22, 2026
|
|
Einride and IonQ Partnership Uses Quantum Computing to Optimize the Logistics of Electric and Autonomous Freight | Jan 22, 2026
|
|
Daikin Applied Invests $163M in Advanced R&D Test Lab to Bolster HVAC Innovation for Data Centers and Beyond | Jan 22, 2026
|
|
Lumana Surpasses 50,000 Cameras, Cementing Its Leadership in AI Video Surveillance | Jan 22, 2026
|
|
|
